Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Derived Stem Cell Transplantation in T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients with type 2 diabetes mellitus between 30 and 70 years of age.~* Failure to triple oral hypoglycemic agent and on stable doses of insulin for at least 3 months.~* On vildagliptin,pioglitazone and metformin for at least 3 months along with Insulin to maintain euglycemia.~* HbA1c \< 7.5%.~* Insulin requirement ≥0.4 IU/kg/d.~* GAD antibody negative status.~Exclusion Criteria:~* Patients with type 1 diabetes mellitus or secondary diabetes.~* Patients with serum creatinine \> 1.5 mg/dl.~* Abnormal liver function tests (defined as value of transaminases \> 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory).~* History of cholecystitis/ cholelithiasis/ cholecystectomy~* Seropositivity for HIV, HBsAg and hepatitis C virus (HCV).~* History of myocardial infarction or unstable angina in the previous 3 months.~* History of malignancy~* Patients with active infections.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- mesenchymal stem cell transplantation (Type: EXPERIMENTAL): Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4unit/Kg for blood glucose control.
- Control (Type: SHAM_COMPARATOR): vildagliptin+metformin+pioglitazone and on Insulin \>0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
- MNC's TRANSPLANTATION (Type: EXPERIMENTAL): Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4unit/Kg for blood glucose control.

Based on this trial design, predict the completion outcome and termination type (if applicable).